Includes data on early use of high-efficacy DMTs, risks of undertreatment of MS, safety issues and de-risking anti-CD20 therapy during long-term use.
16 slides
Latest News
Selected highlights from CMSC 2023
June 6, 2023The Consortium of MS Clinics (CMSC) annual meeting concluded on June 3, 2023. The following are some selected highlights from the symposium. Read More
NfL – a guide to use in MS practice
May 31, 2023Neurofilament-light chain (NfL) has emerged as one of the more promising biomarkers in multiple sclerosis. Neurofilaments are proteins expressed by axons and released into the cerebrospinal fluid, a process that is accelerated with neuroaxonal damage. It has not been determined if elevated concentrations of NfL are due to increased expression and/or release of NfL, impaired clearance of NfL by microglia, or other factors. While the current understanding of NfL is incomplete, an elevated concentration in CSF, plasma or serum, although not specific to MS, is a potentially useful biomarker of axonal damage. Read More
AAN update on anti-CD20 agents: long-term data
May 10, 2023SPECIAL REPORT
Long-term treatment of multiple sclerosis with anti-CD20 therapies is associated with sustained efficacy and a favourable safety profile, according to new data presented at the American Academy of Neurology (AAN) annual meeting, held April 22-27 in Boston. The following summarizes some of the key data that were presented. Read More